Exousia Pro Holding Management

Exousia Pro Holding Management is a subsidiary of Exousia Pro, Inc., a clinical-stage biotechnology company focused on advanced exosome-based delivery systems. The company leverages a proprietary plant-based exosome platform to deliver nucleic acids and gene expression modulating agents, with a primary therapeutic focus on oncology, specifically Glioblastoma multiforme. In addition to therapeutics, the company is developing a non-invasive universal cancer screening test utilizing exosomal NANOG DNA as a diagnostic marker. Exousia Pro operates through several specialized divisions, including Exousia AI for therapeutic development and Exousia Health for commercialization and telehealth integration. The company recently received Orphan Drug Designation from the FDA for its exosome-based treatment of malignant glioma. Through strategic acquisitions and partnerships, such as with the University of Central Florida, the company aims to bridge the gap between clinical innovation and patient access.